AIMEDBIO is a spin-off company from Samsung Medical Center (SMC) established in August 2018. AIMEDBIO aims to provide therapeutic solutions to patients with serious brain diseases, including neuro-oncological and -degenerative diseases, to save patients' lives and improve patients' quality of life. Based on solid global networks with key opinion leaders in the field, an excellent research team with profound achievements, and R&D pipelines with an outstanding drug development platform, AIMEDBIO is an emerging leader in innovative brain disease treatment. The brain, the major constituent of the CNS, is the most sophisticated organ that controls most of the activities of our body, using 20% of total energy intake. To prevent this important organ from various toxic substances, the human body has a highly controlled and protective environment for the brain, such as the blood-brain barrier (BBB) and brain-specific immune systems. Therefore, it is hard to see effects with ordinary treatments in brain diseases, and drug development for the brain is very challenging. However, since brain damage regulates the overall immune system, - especially brain tumors, which significantly impact the effectiveness of immuno-oncology drugs, unmet clinical demands in the treatment of brain diseases are increasing even more.

AIMEDBIO’s biggest strength lies in the fact that it is positioned in an environment where these different approaches are available. We call the coalescence of these approaches a “brain-oriented multi-disciplinary platform”. With our CEO and many clinical advisory board members who are actively engaged in patient care, AIMEDBIO is in a good position to identify clinical unmet needs. Based on this understanding of the patients’ needs, AIMEDBIO uses its brain-oriented multi-disciplinary platform, consisting of largely five parts - big data, antibody-drug conjugate, blood-brain barrier penetration, brain immune modulation and patient-derived model (PDC/PDX), along the development process of therapeutics for brain diseases.

Private

Biotech